Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Harvard University launched LabXchange in January and the free science education platform acquired new resonance during the COVID-19 lockdowns that saw millions of students around the world move ...

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

Presentation Unidentified Speaker Thank you. Thank you, Julianne. Good afternoon, everyone, and welcome to our 4th-quarter ...

Amgen stock skidded late Tuesday after the biotech behemoth said the FDA placed one of its obesity treatments on clinical hold.

Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha ...

Biotechnology specialist Amgen (NASDAQ:AMGN) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS ...

Amgen was founded in 1980 and today employs ... the town council and Mayor Dick Sears at the time said we want to become a life science, bioscience hub. How do we get there?” ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Amgen, Inc. ( NASDAQ: AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - ...

Amgen CEO Bob Bradway stood in Holly Springs ... We delivered the investment in creating high-paying attractive science-based jobs as a result.” The Tax Cuts and Jobs Act of 2017, the TCJA ...